Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer Read more about Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer
Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) using a Closed Transduction System Read more about Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) using a Closed Transduction System
Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders Read more about Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders
Bi-weekly Cetuximab and XELIRI(Capecitabine and Irinotecan) as first line therapy in K/N-RAS wild type advanced colorectal cancer: Phase I-II CETUXIRI study Read more about Bi-weekly Cetuximab and XELIRI(Capecitabine and Irinotecan) as first line therapy in K/N-RAS wild type advanced colorectal cancer: Phase I-II CETUXIRI study